Campbell Bradley L's Form 4 filing
Amicus Therapeutics, Inc. (FOLD) · filed Jan 4, 2024
- Accession no.
- 0000950170-24-002134
- Filed
- Jan 4, 2024
- Trade date
- Jan 2-3, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $225.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Campbell Bradley LCIK 0001400971 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2024 | Common Stock | AGrant or awardAcquired | +153,810 | $0.00 | $0 | 963,257 | Direct | |
| Jan 2, 2024 | Common Stock | FTax withholdingDisposed | −15,452 | $14.24 | −$220,036.48 | 947,805 | Direct | |
| Jan 2, 2024 | Common Stock | MOption exerciseAcquired | +7,500 | $8.61 | +$64,575 | 955,305 | Direct | |
| Jan 2, 2024 | Common Stock | SSaleDisposed | −7,500 | $14.24 | −$106,800 | 947,805 | Direct | |
| Jan 2, 2024 | Common Stock | MOption exerciseAcquired | +8,333 | $12.28 | +$102,329.24 | 956,138 | Direct | |
| Jan 2, 2024 | Common Stock | SSaleDisposed | −8,333 | $14.23 | −$118,578.59 | 947,805 | Direct | |
| Jan 3, 2024 | Common Stock | FTax withholdingDisposed | −41,474 | $13.53 | −$561,143.22 | 906,331 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2024 | Common Stock | AGrant or awardAcquired | +265,517 | $0.00 | $0 | 265,517 | Direct | |
| Jan 2, 2024 | Common Stock | MOption exerciseDisposed | −7,500 | $0.00 | $0 | 82,500 | Direct | |
| Jan 2, 2024 | Common Stock | MOption exerciseDisposed | −8,333 | $0.00 | $0 | 91,667 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.